Cytotoxic T lymphocytes (CTL) play an important role in the control of viral infections, including those caused by influenza viruses. It has been shown that in mice, CTL contribute to protective immunity against influenza viruses of various subtypes (25) . In addition, influenza A virus-specific CTL in humans were found to reduce virus titers in the lungs and morbidity upon infection (27) . To evade host CTL responses, viruses have developed a variety of mechanisms to prevent recognition by specific CTL (24, 30) . These mechanisms involve major histocompatibility complex (MHC) class I downregulation, as described for the human immunodeficiency virus type 1 Nef protein (11, 40) and the adenovirus E3/19K protein (8) , and blocking of antigen presentation of viral epitopes, as described for certain herpesvirus proteins (22, 23) . Alternatively, viruses can accumulate in or adjacent to CTL epitopes mutations that affect peptide processing and presentation, binding to MHC class I molecules, and/or recognition by specific T cells (20, 45) . This escape mechanism has been described predominantly for chronic virus infections, such as those caused by lymphocytic choriomeningitis virus (29, 32) , Epstein-Barr virus (1, 9, 13, 14, 17) , human immunodeficiency virus (7, 12, 18, 19, 24, 28, 31, 33, 34) , hepatitis B virus (2, 3) , and hepatitis C virus (10, 44) .
Recently, amino acid sequence variations in CTL epitopes in the nucleoprotein (NP) of influenza A viruses were identified (5, 41) . In the HLA-B * 3501-restricted epitope NP [418] [419] [420] [421] [422] [423] [424] [425] [426] (NP containing residues 418 to 426), variations were observed in the T-cell receptor contact residues (5) . These variants emerged in a chronological order, and CTL specific for older variants failed to recognize the mutated versions of the same epitope. In addition, an amino acid sequence variation was observed at position 384 of the NP. An arginine at this position is an anchor residue for the HLA-B * 0801-restricted epitope NP 380-388 (ELRSRYWAI) and the HLA-B * 2705-restricted epitope NP 383-391 (SRYWAIRTR) (21) . The observed R384G mutation resulted in the loss of the anchor residue and, as a result, abolished recognition by CTL (37, 41) . Although the rapid fixation of the mutation was explained by small selective advantages and population dynamics in a theoretical model (16) , it is unclear to what extent a single amino acid substitution in a CTL epitope affects the overall virus-specific CTL response in humans.
In this study, this issue was addressed in vitro by using peripheral blood mononuclear cells (PBMC) from HLA-B * 2705-positive individuals and genetically engineered recombinant influenza viruses containing an arginine or a glycine at position 384 (but otherwise identical) and therefore possessing or not possessing the HLA-B that the R384G substitution significantly impaired the influenza virus-specific CTL response in vitro.
MATERIALS AND METHODS
Plasmids and site-directed mutagenesis. For the generation of recombinant influenza viruses, RNA was extracted from culture supernatants containing influenza virus A/Netherlands/18/94 (A/NL/18/94) by using a High Pure RNA isolation kit (Roche Diagnostics GmbH, Mannheim, Germany). The RNA was used in a single-tube reverse transcription-PCR to amplify viral NP segments. After annealing of the primers AGCAAAAGCAGGGT and AGTAGAAACA AGGGTATTTTTC, first-strand synthesis was carried out with 50-l volumes of 20 mM Tris-HCl buffer (pH 8.8) containing 10 mM KCl, 10 mM (NH 4 ) 2 SO 4 , 2 mM MgSO 4 , 0.1% Triton X-100, 0.1 mg of bovine serum albumin (BSA)/ml, 10 mM deoxynucleoside triphosphates, 10 mM dithiothreitol, RNasin, 5 IU of Superscript II reverse transcriptase, and 5 IU of Pfu Turbo DNA polymerase (Stratagene, La Jolla, Calif.). After incubation for 45 min at 42°C, the mixture was heated at 95°C for 3 min, followed by 40 cycles of denaturation (1 min at 95°C), annealing (2 min at 37°C), and elongation (3 min at 72°C). For the addition of BsaI restriction sites, an additional amplification of 30 cycles was performed with the primers CTAGGTCTCTTATTAGTAGAAACAAGG and GGGAGGTCTCCGGCCAGCAAAAGCAGG (underlining indicates restriction sites). The amplicon was purified by electrophoresis on agarose gels according to standard methods and inserted between the human polymerase I promoter and the hepatitis delta ribozyme sequence of plasmid pSP72-PhuThep (15) .
For site-directed mutagenesis, the coding sequence of the NP gene of influenza virus A/NL/18/94 was amplified by PCR with the primers CAGCGGCCG CATGGCGTCCCAAGGC and CACTCGAGTTAATTGTCGTACTCCT CTGC and cloned into pBluescript (Stratagene) after digestion with NotI and XhoI. Using this plasmid as a template, site-directed mutagenesis was performed by PCR in order to obtain an arginine at position 384 instead of a glycine (G384R) as previously described (39) . The mutated sequence was exchanged by using restriction site SphI in the NP gene and restriction site XhoI in pBluescript, 3Ј of the insert. Subsequently, the SacI fragment with the mutation at position 384 was exchanged for SacI fragments in genomic constructs of the NP gene of influenza A virus A/NL/18/94. The nucleotide sequences of all cloned NP genes were determined by using standard procedures as previously described (41) in order to confirm the identity of the sequences.
Plasmid pHMG-NP, from which the NP of influenza virus A/PR/8/34 was transcribed, was kindly provided by P. Palese. The bidirectional reverse genetics plasmids pHW181 through pHW188 for the transcription of viral gene segments of influenza virus A/WSN/33 were kindly provided by R. G. Webster.
Generation of viruses. The unidirectional plasmid of the genomic construct of the NP of A/NL/18/94 was transfected into 293T cells with the bidirectional constructs containing the PB1, PB2, PA, HA, NA, M, and NS gene segments of A/WSN/33 and pHMG-NP expressing the NP of PR/8/34. For this purpose, 10 6 293T cells were cultured overnight in Dulbecco minimal essential medium (Cambrex, East Rutherford, N.J.) supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, and 100 IU of penicillin/ml and 100 g of streptomycin/ml (antibiotics) in gelatin-coated 10-cm petri dishes. The cells then were transfected with 5 g of each of the plasmids by the calcium phosphate precipitation method as described previously (15) . After 24 h, the cells were washed with phosphate-buffered saline (PBS), and 10 ml of Dulbecco minimal essential medium containing 2% FCS was added. After another 24 h, the culture supernatants of the transfected 293T cells were harvested, and infectious virus titers were determined as previously described (36) . Titers of 10 3 50% tissue culture infective doses/ml were obtained routinely with the A/NL/94-384G and A/NL/94-384R constructs. Subsequently, virus stocks were prepared by infecting confluent Madin-Darby canine kidney (MDCK) cells in 162-cm 2 flasks with 1 ml of supernatant from the transfected 293T cells in 4 ml of Eagle minimal essential medium (Cambrex) supplemented with 4% BSA, 0.02 M HEPES, 0.01 M NaHCO 3 , antibiotics, and 0.1% trypsin (infection medium) at 37°C for 1 h. The cells were washed once with PBS and then cultured at 37°C in infection medium. After 3 days, culture supernatants were harvested, cleared by low-speed centrifugation, divided into aliquots, and stored at Ϫ70°C until use. Viruses with the NP 383-391 epitope and viruses without the NP 383-391 epitope were designated A/NL/94-384R and A/NL/94-384G, respectively. Upon infection of MDCK cells, virus titers were amplified up to 10 7 50% tissue culture infective doses/ml for both viruses. PBMC. PBMC from healthy HLA-B * 2705-positive blood donors were isolated from heparinized blood (Sanquin Bloodbank, Rotterdam, The Netherlands) by density gradient centrifugation with lymphocyte separation medium (ICN Biomedicals/Cappel, Aurora, Ohio) and cryopreserved at Ϫ135°C. Genetic subtyping was performed in the Laboratory for Histocompatibility and Immunogenetics at the Sanquin Bloodbank by using a commercial typing system (GenoVision, Vienna, Austria).
In vitro stimulation of PBMC with influenza A viruses. PBMC were resuspended in RPMI 1640 medium containing 25 mM HEPES buffer and L-glutamine (Cambrex) and supplemented with 10% FCS and antibiotics (R10F). Five million PBMC were infected with influenza virus A/NL/94-384G, A/NL/94-384R, or Resvir-9, a reassortant of strains A/Puerto Rico/8/34 (H1N1) and A/Nanchang/933/95 (H3N2) containing the NP, HA, and NA of A/Nanchang/933/95. A multiplicity of infection of 3 in a volume of 5 ml of R10F was used as described previously (4) . After 1 h at 37°C, the cells were resuspended in RPMI 1640 medium supplemented with 10% human AB serum (Sanquin Bloodbank), antibiotics, and 20 M ␤-mercaptoethanol and added to noninfected PBMC at a ratio of 1:1 in a 25-cm 2 culture flask. After 48 h of stimulation, recombinant interleukin 2 was added to a final concentration of 50 IU/ml. After an additional 7 to 8 days, the cells were used as effector cells in 51 Cr release assays and for the enumeration of virus-specific CD8 ϩ T cells by intracellular gamma interferon (IFN-␥) staining (see below). CD8 ؉ -T-cell clones. The generation of a CD8 ϩ -T-cell clone directed against the HLA-B * 2705-restricted epitope NP 383-391 derived from the NP was described previously (41) . A CD8
ϩ -T-cell clone directed against the immunodominant and conserved HLA-A * 0201-restricted epitope M1 58-66 derived from the matrix protein (M1) was established by similar procedures.
Isolation of CD8 ؉ T cells. CD8 ϩ T cells were isolated from effector cell populations by magnetic sorting with a CD8 ϩ cell selection kit (Dynal Biotech GmbH, Hamburg, Germany). The cells were washed once with PBS supplemented with 2% FCS (P2F) and subsequently resuspended in P2F at a concentration of 10 7 /ml. Capture Dynabeads were added to the cell suspension at a Dynabead/CD8
ϩ -T-cell ratio of 8:1. After 30 min of incubation on ice, the mixture of Dynabeads and cells was washed five times with 5.0 ml of P2F. The Dynabeads, together with the attached cells, were reconstituted in 200 l of RPMI 1640 medium supplemented with 1% FCS. To detach the cells from the Dynabeads, 20 l of DETACHaBEAD (Dynal Biotech) was added. After 1 h of incubation at 20°C, the released cells were isolated, washed once with R10F, and used as effector cells in 51 Cr release assays with C1R cells as target cells. Target cells. Autologous B-lymphoblastoid cell lines (BLCL), produced as described previously (38) , and two C1R cell lines, kindly provided by P. Romero (C1R cell line) and J. Lopez de Castro (HLA-B * 2705-transfected C1R cell line [C1R-B27]), were used as target cells. Peptide labeling was performed by incubating 10 6 cells overnight with 5 M peptide in 1 ml of R10F. Peptides were manufactured, purified by high-pressure liquid chromatography, and analyzed by mass spectrometry (Eurogentec, Seraing, Belgium). For exogenous protein labeling, 50 g of recombinant influenza virus NP (rNP), derived from influenza virus A/HK/2/68 (rNP-HK) or A/NL/18/94 (rNP-NL), was added to 10 6 cells in 1 ml of R10F as described previously (42) . For infection with influenza virus A/NL/94-384G and A/NL/94-384R, target cells were infected at a multiplicity of infection of 3 in a volume of 1 ml. After incubation for 1 h at 37°C, the cells were resuspended in R10F and incubated for 16 to 18 h. BLCL and C1R cells were equally susceptible to infection with influenza virus A/NL/94-384G and A/NL/ 94-384R, as determined by immunofluorescence assays with a fluorescein isothiocyanate-conjugated monoclonal antibody (MAb; Dako, Glostrup, Denmark) directed to the NP.
51 Cr release assays. Target cells were resuspended in RPMI 1640 medium supplemented with 0.1% BSA and antibiotics (R0.1B). Next, 5 ϫ 10 5 target cells were labeled with 50 Ci of Na 2 [
51 Cr]O 4 in R0.1B for 1 h at 37°C. After incubation, the cells were washed three times with R10F and adjusted to a concentration of 10 5 /ml. Subsequently, 50-l samples of target cells were incubated with PBMC stimulated in vitro with influenza virus A/NL/94-384G or A/NL/94-384R at effector cell/target cell (E/T) ratios of 80, 40, 20, 10, or 5 or with purified CD8
ϩ -T-cell populations or T-cell clones at E/T ratios of 10, 5, 2.5, and 1. Target cells were also incubated with 100 l of 10% Triton X-100 or R10F to determine maximum release and spontaneous release, respectively. After 4 h of incubation at 37°C, the supernatants were harvested (Skatron Instruments, Sterling, Va.), and radioactivity was measured by gamma counting. The percentage of specific lysis was calculated with the following formula: (experimental release Ϫ spontaneous release)/(maximum release Ϫ spontaneous release) ϫ 100%. 51 Cr release assays were performed in triplicate or quadruplicate, and the data are presented as averages. 
RESULTS

Validation of infection with influenza viruses A/NL/94-384G
and A/NL/94-384R in vitro. To verify that target cells were equally susceptible to infection with influenza virus A/NL/94-384G and A/NL/94-384R, immunofluorescence assays were performed with BLCL infected with either virus. It was found that the numbers of infected cells were similar, as determined by positive staining for NP (data not shown). In addition, the expression of MHC class I-bound epitopes on the surface of BLCL infected with influenza A viruses A/NL/94-384G and A/NL/94-384R and the subsequent recognition by CTL were compared to confirm that they were on the same order of magnitude (Fig. 1) . To this end, (Fig.   1B) . In contrast, the CTL clone specific for M1 58-66 recognized A/NL/94-384G-and A/NL/94-384R-infected target cells equally well, indicating that the infection of cells and the processing and presentation of immunogenic peptides were comparable for both viruses (Fig. 1A) .
In vitro stimulation of PBMC with recombinant influenza viruses. Viruses A/NL/94-384G and A/NL/94-384R were used for the stimulation of PBMC obtained from an HLA-A * 0201-and HLA-B * 2705-positive blood donor to demonstrate that the R384G mutation resulted in the depletion of a CTL response against the NP 383-391 epitope. As shown in Fig.2A (Fig. 2H) . Similar results were observed for the other donors. The absence of CD8 ϩ T cells specific for the NP 383-391 epitope, as measured by intracellular IFN-␥ staining, coincided with the lack of capacity of the PBMC culture to lyse target cells pulsed with the NP 383-391 peptide but not those pulsed with the M1 58-66 peptide or the NP 174-184 peptide (Fig.  2, bottom panels) .
Magnitude of the influenza virus-specific CTL response in vitro. The contribution of the NP 383-391 epitope to the influenza A virus-specific CTL response was determined by measuring the proportions of CD3 ϩ CD8 ϩ IFN-␥ ϩ cells in PBMC cultures stimulated with influenza virus A/NL/94-384G or A/NL/94-384R. IFN-␥ expression was induced by restimulation with autologous BLCL or C1R-B27 cells infected with the respective influenza viruses or incubated with rNP or peptides. Figure 3 shows such an analysis for donor 2 after restimulation with autologous BLCL. A response was observed after restimulation with BLCL incubated with the NP 383-391 peptide or rNP-HK in PBMC cultures expanded after stimulation with influenza virus A/NL/94-384R. Such a response was not observed after restimulation with rNP-NL, which lacks the NP 383-391 epitope (Fig. 3, right) . After primary stimulation with influenza virus A/NL/94-384G, no response was observed after restimulation with the NP 383-391 peptide or rNP (Fig. 3,  left) . In addition, no differences were observed for the influenza virus A/NL/94-384G-stimulated culture in the in vitro recall response induced by influenza viruses A/NL/94-384G and A/NL/94-384R. However, the CTL response against influenza virus A/NL/94-384G was significantly lower than the response to influenza virus A/NL/94-384R in PBMC cultures that were stimulated with influenza virus A/NL/94-384R.
These differences are depicted for all donors tested as the percentage of virus-specific IFN-␥ ϩ CD8 ϩ T cells in PBMC cultures (Fig. 4A) and as the percentage of virus-specific IFN-␥ ϩ cells in the CD8 ϩ -T-cell fraction (Fig. 4B) , ranging from 1 to 9% and 1 to 20%, respectively. Since no differences were observed after primary stimulation with a virus lacking the NP 383-391 epitope, these results show that depletion of this epitope resulted in a substantial decrease in the influenza A virus-specific CTL response in vitro. The relative reduction in the CTL response in- duced by the virus without the NP 383-391 epitope compared to the response against the virus with the NP 383-391 epitope ranged from 2 to 46%, with a median of 30% (Fig. 4) . When C1R-B27 cells were used for the restimulation of PBMC cultures stimulated with influenza virus A/NL/94-384G or A/NL/94-384R, comparable results were obtained (data not shown). As expected, the percentage of virus-specific CTL restricted by a single HLA allele was lower than the percentage measured after restimulation with autologous BLCL. On average, the HLA-B * 2705-restricted response constituted 65% of the response measured over all HLA alleles when autologous BLCL were used.
PBMC cultures stimulated with influenza viruses A/NL/94-384G and A/NL/94-384R were also tested in parallel in 51 Cr release assays. In contrast to the results obtained with intracellular IFN-␥ staining, no clear differences were observed for the lysis of target cells infected with influenza virus A/NL/94-384G or A/NL/94-384R by PBMC expanded after stimulation with influenza virus A/NL/94-384R (Fig. 5A and B) . However, when protein-labeled BLCL or C1R-B27 cells were used as target cells, PBMC cultures stimulated with influenza virus A/NL/94-384R recognized target cells labeled with rNP-HK but failed to recognize target cells labeled with rNP-NL, containing the R384G mutation (Fig. 5D) . PBMC cultures stimulated with influenza virus A/NL/94-384G failed to recognize protein-labeled target cells at all (Fig. 5C ). These findings indicate that the NP 383-391 epitope constitutes an important CTL epitope recognized in the NP-specific CTL response of these donors. 
DISCUSSION
In the present study, the effect of a single amino acid substitution in epitope NP 383-391 on the in vitro human CTL response specific for influenza A virus was investigated by using recombinant influenza viruses differing only at position 384 of the NP. When these influenza viruses were used for the stimulation of PBMC obtained from HLA-B * 2705-positive individuals, it was found that the mutation reduced the magnitude of the virus-specific CTL response in vitro.
Before influenza viruses A/NL/94-384G and A/NL/94-384R were compared for their capacities to induce CTL responses in vitro, it was confirmed that BLCL and C1R cells were equally susceptible to infection with these two viruses and that the antigen processing and presentation of MHC class I peptide complexes on the surface of these cells were on the same order of magnitude when a CTL clone specific for the M1 58-66 epitope was used. Furthermore, the presence and absence of the NP 383-391 epitope in influenza viruses A/NL/94-384R and A/NL/94-384G, respectively, were confirmed by using an NP 383-391 -specific CTL clone and PBMC that were obtained from HLA-B * 2705-positive individuals and that were stimulated in vitro with these viruses.
Stimulation of HLA-B (Tables 1 and 2 ). The responses to influenza virus A/NL/94-384G were similar in PBMC stimulated with influenza viruses A/NL/94-384G and A/NL/94-384R. However, in PBMC stimulated with influenza virus A/NL/94-384R, a lower frequency of influenza virus A/NL/94-384G-specific cells than of influenza virus A/NL/94-384R-specific cells was observed. This difference was used as a measure of the reduction in the virus-specific CTL response by the loss of the NP 383-391 epitope. In four out of five donors tested, a significant reduction in the number of influenza A virus-specific CD8 ϩ CTL was measured. Thus, the loss of a single epitope can have a major impact on the CTL response in vitro. The absence of a reduction in donor 1 correlated with the subdominant nature of the NP 383-391 epitope in this donor (Table  2) . Overall, there was a correlation between the frequency of NP 383-391 -specific CTL in PBMC cultures stimulated with A/NL/ 94-384R and the reduction in the CTL response after stimulation with an influenza virus lacking the NP 383-391 epitope.
Since three of the five donors tested were also HLA-B * 0801 positive, it is possible that the loss of the HLA-B * 0801-restricted NP 380-388 epitope also contributed to the reduction in the CTL response in these donors. It should be noted, however, that the NP 380-388 epitope is a minor epitope, especially in the presence of an HLA-B * 2705-restricted response (4); therefore, its loss could be only marginally responsible for the observed reduction in the CTL response.
The differences in CTL responses measured by intracellular IFN-␥ staining were not detected in 51 Cr release assays when virus-infected BLCL were used as target cells. The resolution of the 51 Cr release assays may not be sufficient to detect such differences, considering the reduction in frequency (1 to 9%) of virus-specific cells in the in vitro-expanded PBMC (which were used as effector cells in these assays) caused by the deletion of the NP 383-391 epitope.
Based on these data, we conclude that the mutation in the NP 383-391 epitope impaired the overall in vitro CTL response directed against influenza virus significantly. However, it is not clear from these studies what the impact of the R384G mutation on the in vivo CTL response in humans is. Of interest, it was recently demonstrated with a mouse model for influenza virus that deletion of a dominant H-2D b -restricted epitope from the NP (NP 366-374 ) of influenza A viruses by site-directed mutagenesis resulted in the loss of a CTL response specific for this epitope in vivo. This finding correlated with a prolonged duration of viral shedding in infected mice and increased mortality rates (43) . Furthermore, the loss of an immunodominant epitope was responsible for prolonged viral shedding (up to 2 months) in RAG-1-deficient mice transgenic for the T-cell receptor specific for that epitope (35) . If infection of humans also results in reduced control of an infection with CTL epitope mutant influenza viruses, it might be expected that HLA-B * 2705-positive individuals would be more susceptible to infection with a mutant virus (lacking the NP 383-391 epitope) than with a wild-type virus. Of interest, prolonged viral shedding in a small proportion of individuals in the human population (e.g., 8% HLA-B * 2705 positive) was sufficient to explain the rapid fixation of the R384G substitution in the CTL NP 383-391 epitope at the population level with a recently developed theoretical model (16, 41) .
Collectively, the data obtained in the present study showed that the loss of an immunodominant epitope through a mutation at an anchor residue affects the CTL response in vitro significantly. It could be speculated that the emergence of influenza A viruses with mutations in CTL epitopes have a profound advantage in individuals expressing the corresponding HLA molecules, eventually leading to the rapid fixation of these mutants (16) . 
